healthcarenewswire

The oligonucleotide synthesis industry is driven by factors such as recent advances in oligonucleotide synthesis, increasing support from government organizations, increasing research activities in synthetic biology, and increasing burden of cancer and infectious diseases.

In terms of application, the oligonucleotide synthesis market is categorized into research, diagnostic and therapeutic. Research has been the largest segment of the market, where it was estimated to contribute 65.2% to the market in 2016. Diagnostic segment is expected to contribute 21.0% revenue to the market in 2023.

Request for sample copy at: http://bit.ly/2pjGtNV

Based on end user, the oligonucleotide synthesis market is categorized into academic research, diagnostic laboratory, pharmaceutical & biotechnology companies, and others. The other end users of oligonucleotide synthesis products include, but are not limited to, food and beverage companies and forensic laboratories. The contribution of academic research institute to the global market was estimated at 42.0% in 2016. The market in diagnostic laboratories are expected to grow at a CAGR of 10.9% during the forecast period.

Europe is one of the key regions for oligonucleotide synthesis market. The European market for oligonucleotide synthesis is expected to reach $743.0 million by 2023. The market is witnessing significant growth, primarily due to the increasing research and development activities, advances in technology, developed infrastructure, and increased public and private funding for the development of novel therapeutics. Moreover, the increase in demand for reducing healthcare cost, high prevalence of cancer and infectious diseases, and high healthcare expenditure fuel the development of the European oligonucleotide synthesis industry. The U.K. is the largest as well as the fastest growing country in the European oligonucleotide synthesis industry. The U.K. and Germany, the second largest market in Europe, are expected to exhibit a CAGR of 10.9% and 10.8%, respectively, higher than the CAGR of 10.5% of the European oligonucleotide synthesis market.

Some of the key players in the oligonucleotide synthesis market include LGC Biosearch Technologies, Inc., Bioautomation Corporation, Integrated DNA Technologies, Inc., GeneDesign, Inc., Trilink Biotechnologies LLC, Merck KGaA, Eurofins Scientific SE, Thermo Fisher Scientific Inc., General Electric Company and Eurogentec S.A.

Source: P&S Intelligence